Clozapine is effective in treating patients with schizophrenia who do not respond to conventional neuroleptic drugs. The drug is unique in that it is available only with a US Food and Drug Administration-mandated system for weekly monitoring of patients' white blood cell counts. No study has been conducted to evaluate the cost-effectiveness of this mandatory monitoring system.
A benchmark case was established by utilizing cumulative incidence rates of agranulocytosis from a recent study with a large sample of clozapine-treated patients. We assumed a 20% mortality among patients with agranulocytosis, $30.61 in monitoring costs each week, and 14.4 years of remaining life expectancy after detection of agranulocytosis. Based on these benchmark assumptions, cost-effectiveness ratios in dollars per quality-adjusted life-year were calculated for the first, second, and third 6-month periods during which a patient was receiving clozapine. Sensitivity analyses were performed with more conservative assumptions in 5 alternative scenarios.
In the benchmark case, costs per quality-adjusted life-year gained were $61 694, $925 418, and $420 644 for the first, second, and third 6-month periods of clozapine treatment, respectively. In the aIternative scenarios, these costs ranged from $7923 to $46 056 for the first 6-month period and from $54 025 to $690 850 for the second and third 6-month periods.
While the costs of monitoring patients with schizophrenia in the first 6-month period of clozapine treatment seem to be justifiable, monitoring thereafter may not be cost-effective because of the very low incidence of agranulocytosis in the later periods.
Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of Clozapine Monitoring After the First 6 Months. Arch Gen Psychiatry. 1996;53(10):954-958. doi:10.1001/archpsyc.1996.01830100104013